Phenotypic T cell exhaustion in a murine model of bacterial infection in the setting of pre-existing malignancy

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Mittal, Rohit ^a   Wagener, Maylene ^b   Breed, Elise R ^a   Liang, Zhe ^a   Yoseph, Benyam P ^a   Burd, Eileen M ^c   Farris III, Alton B ^c   Coopersmith, Craig M ^a   Ford, Mandy L ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR 2B4; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN BTLA; UNCLASSIFIED DRUG; BTLA PROTEIN, MOUSE; CD244 PROTEIN, MOUSE; IMMUNOGLOBULIN RECEPTOR; LEUKOCYTE ANTIGEN; PDCD1 PROTEIN, MOUSE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL INFECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNE RESPONSE; LISTERIA MONOCYTOGENES; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; MALE; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PHENOTYPE; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; ADENOCARCINOMA; ANIMAL; IMMUNOLOGY; LISTERIOSIS; PANCREAS TUMOR; PATHOLOGY; TRANSGENIC MOUSE;

ADENOCARCINOMA; ANIMALS; ANTIGENS, CD; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; INTERFERON-GAMMA; INTERLEUKIN-2; LISTERIA MONOCYTOGENES; LISTERIOSIS; MALE; MICE; MICE, TRANSGENIC; PANCREATIC NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, IMMUNOLOGIC;

EID: 84900450382     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093523     Document Type: Article

References (47)

1. Rangwala S, Tsai KY (2011) Roles of the immune system in skin cancer. Br J Dermatol 165: 953-965.
2. Smyth MJ, Dunn GP, Schreiber RD (2006) Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90: 1-50. (Pubitemid 43765795)
3. del Campo AB, Carretero J, Aptsiauri N, Garrido F (2012) Targeting HLA class I expression to increase tumor immunogenicity. Tissue Antigens 79: 147-154.
4. Pages F, Kroemer G (2011) Prognostic impact of anticancer immune responses: an introduction. Semin Immunopathol 33: 317-319.
5. Campoli M, Chang CC, Ferrone S (2002) HLA class I antigen loss, tumor immune escape and immune selection. Vaccine 20 Suppl 4: A40-45. (Pubitemid 35449404)
6. Preston CC, Goode EL, Hartmann LC, Kalli KR, Knutson KL (2011) Immunity and immune suppression in human ovarian cancer. Immunotherapy 3: 539-556.
7. Khong HT, Wang QJ, Rosenberg SA (2004) Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother 27: 184-190. (Pubitemid 39118082)
8. Ferrone S, Whiteside TL (2007) Tumor microenvironment and immune escape. Surg Oncol Clin N Am 16: 755-774, viii. (Pubitemid 350101281)
9. Wherry EJ (2011) T cell exhaustion. Nat Immunol 12: 492-499.
10. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, et al. (2009) Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 10: 29-37.
11. Krempski J, Karyampudi L, Behrens MD, Erskine CL, Hartmann L, et al. (2011) Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol 186: 6905-6913.
12. Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, et al. (2012) CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res 72: 887-896.
13. Ott PA, Hodi FS, Robert C (2013) CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 19: 5300-5309.
14. Ye J, Ma C, Wang F, Hsueh EC, Toth K, et al. (2013) Specific recruitment of gammadelta regulatory T cells in human breast cancer. Cancer Res.
15. Schmidt HH, Ge Y, Hartmann FJ, Conrad H, Klug F, et al. (2013) HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients. Oncoimmunology 2: e24962.
16. Motz GT, Coukos G (2013) Deciphering and reversing tumor immune suppression. Immunity 39: 61-73.
17. Baniyash M, Sade-Feldman M, Kanterman J (2013) Chronic inflammation and cancer: suppressing the suppressors. Cancer Immunol Immunother.
18. Mook P, O'Brien SJ, Gillespie IA (2011) Concurrent conditions and human listeriosis, England, 1999-2009. Emerg Infect Dis 17: 38-43.
19. (2013) Vital signs: Listeria illnesses, deaths, and outbreaks - United States, 2009-2011. MMWR Morb Mortal Wkly Rep 62: 448-452.
20. Danai PA, Moss M, Mannino DM, Martin GS (2006) The epidemiology of sepsis in patients with malignancy. Chest 129: 1432-1440. (Pubitemid 43894970)
21. Fox AC, Breed ER, Liang Z, Clark AT, Zee-Cheng BR, et al. (2011) Prevention of lymphocyte apoptosis in septic mice with cancer increases mortality. J Immunol 187: 1950-1956.
22. Fox AC, Robertson CM, Belt B, Clark AT, Chang KC, et al. (2010) Cancer causes increased mortality and is associated with altered apoptosis in murine sepsis. Crit Care Med 38: 886-893.
23. Liyanage UK, Goedegebuure PS, Moore TT, Viehl CT, Moo-Young TA, et al. (2006) Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. J Immunother 29: 416-424. (Pubitemid 44288954)
24. Viehl CT, Moore TT, Liyanage UK, Frey DM, Ehlers JP, et al. (2006) Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann Surg Oncol 13: 1252-1258. (Pubitemid 44440427)
25. Floyd TL, Koehn BH, Kitchens WH, Robertson JM, Cheeseman JA, et al. (2011) Limiting the Amount and Duration of Antigen Exposure during Priming Increases Memory T Cell Requirement for Costimulation during Recall. The Journal of Immunology 186: 2033-2041.
26. Shen H, Miller JF, Fan X, Kolwyck D, Ahmed R, et al. (1998) Compartmentalization of bacterial antigens: differential effects on priming of CD8 T cells and protective immunity. Cell 92: 535-545. (Pubitemid 28101116)
27. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, et al. (1994) T cell receptor antagonist peptides induce positive selection. Cell 76: 17-27. (Pubitemid 24035278)
28. van der Windt GJ, van 't Veer C, Florquin S, van der Poll T (2010) CD44 deficiency is associated with enhanced Escherichia coli-induced proinflammatory cytokine and chemokine release by peritoneal macrophages. Infect Immun 78: 115-124.
29. Karakatsanis S, Bertsias G, Roussou P, Boumpas D (2013) Programmed death 1 and B and T lymphocyte attenuator immunoreceptors and their association with malignant T-lymphoproliferative disorders: brief review. Hematol Oncol.
30. Derre L, Rivals JP, Jandus C, Pastor S, Rimoldi D, et al. (2010) BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest 120: 157-167.
31. Paulos CM, June CH (2010) Putting the brakes on BTLA in T cell-mediated cancer immunotherapy. J Clin Invest 120: 76-80.
32. Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, et al. (2013) T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 121: 1612-1621.
33. Amarnath S, Mangus CW, Wang JC, Wei F, He A, et al. (2011) The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med 3: 111ra120.
34. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, et al. (2013) Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells. Sci Transl Med 5: 200ra116.
35. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264.
36. Yao S, Zhu Y, Chen L (2013) Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov 12: 130-146.
37. Yang B, Wang X, Jiang J, Cheng X (2013) Involvement of CD244 in regulating CD4+ T cell immunity in patients with active tuberculosis. PLoS One 8: e63261.
38. Bengsch B, Seigel B, Ruhl M, Timm J, Kuntz M, et al. (2010) Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog 6: e1000947.
39. Schlaphoff V, Lunemann S, Suneetha PV, Jaroszewicz J, Grabowski J, et al. (2011) Dual function of the NK cell receptor 2B4 (CD244) in the regulation of HCV-specific CD8+ T cells. PLoS Pathog 7: e1002045.
40. Goding SR, Wilson KA, Xie Y, Harris KM, Baxi A, et al. (2013) Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol 190: 4899-4909.
41. Joshi NS, Cui W, Chandele A, Lee HK, Urso DR, et al. (2007) Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity 27: 281-295. (Pubitemid 47284924)
42. Sarkar S, Teichgraber V, Kalia V, Polley A, Masopust D, et al. (2007) Strength of stimulus and clonal competition impact the rate of memory CD8 T cell differentiation. J Immunol 179: 6704-6714.
43. Cui W, Joshi NS, Jiang A, Kaech SM (2009) Effects of Signal 3 during CD8 T cell priming: Bystander production of IL-12 enhances effector T cell expansion but promotes terminal differentiation. Vaccine 27: 2177-2187.
44. Keppler SJ, Rosenits K, Koegl T, Vucikuja S, Aichele P (2012) Signal 3 cytokines as modulators of primary immune responses during infections: the interplay of type I IFN and IL-12 in CD8 T cell responses. PLoS One 7: e40865.
45. Wilson DC, Matthews S, Yap GS (2008) IL-12 signaling drives CD8+ T cell IFN-gamma production and differentiation of KLRG1+ effector subpopulations during Toxoplasma gondii Infection. J Immunol 180: 5935-5945.
46. Huang X, Venet F, Wang YL, Lepape A, Yuan Z, et al. (2009) PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci U S A 106: 6303-6308.
47. Shubin NJ, Chung CS, Heffernan DS, Irwin LR, Monaghan SF, et al. (2012) BTLA expression contributes to septic morbidity and mortality by inducing innate inflammatory cell dysfunction. J Leukoc Biol 92: 593-603.